Bristol Myers Squibb Co. closed 6.82% below its 52-week high of $63.33, which the company reached on March 11th.

K reports of America’s largest pharmaceutical companies show that they continue to avoid paying much, if any, U.S. corporate income tax.

Squibb announced that the European Commission has granted approval to Breyanzi, a CD19-directed chimeric antigen receptor T ...

While modern society’s relationship with mental health as evolved in recent decades, pharmaceutical innovation has yet to keep pace, mostly due ...

DelveInsight's "ROZLYTREK Market Size, Forecast, and Market Insight Report" highlights the details around ROZLYTREK, an ...

This was the stock's second consecutive day of losses.

BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies ...

DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase ...

Local economies depend on grant recipients, the letter said, "to conduct critical research that drives industry innovation." ...

ReviveMed's AI platform analyzes metabolite data, revealing insights into diseases and streamlining drug development for ...

Actor Taye Diggs sits down with TODAY’s Jenna Bush Hager and guest co-host Regina Hall to talk about Bristol Myers Squibb, an organization that he is an ambassador for and opens up about how the ...

Although new U.S. tariffs on Canada, Mexico, and China are putting pressure on markets, investors are shifting toward ...